SonALAsense
Berkeley
About SonALAsense
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $67.1M
- Funding stage: Early Stage Venture
- Last round: Grant (Dec 2024)
- Website: sonalasense.com
- Phone: 510-831-2220
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/sonalasense-17595 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.